Analysis: Rival Treatments May Help Justify FDA Gamble with Biogen Alzheimer’s Drug

Data from clinical trials of three experimental Alzheimer’s disease drugs expected to start emerging next year could help shed light on whether U.S. regulators were justified in their controversial approval of a Biogen Inc (BIIB.O) treatment without clear evidence that it works.